Phapros Tbk PT (PEHA) - Total Assets
Based on the latest financial reports, Phapros Tbk PT (PEHA) holds total assets worth Rp1.45 Trillion IDR (≈ $85.07 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Phapros Tbk PT - Total Assets Trend (2011–2025)
This chart illustrates how Phapros Tbk PT's total assets have evolved over time, based on quarterly financial data. Also see PEHA company net worth for the company's overall valuation and market capitalisation.
Phapros Tbk PT - Asset Composition Analysis
Current Asset Composition (December 2025)
Phapros Tbk PT's total assets of Rp1.45 Trillion consist of 46.3% current assets and 53.7% non-current assets. Review Phapros Tbk PT (PEHA) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (IDR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rp70.40 Billion | 8.7% |
| Accounts Receivable | Rp350.22 Billion | 25.3% |
| Inventory | Rp153.13 Billion | 11.0% |
| Property, Plant & Equipment | Rp467.98 Billion | 33.7% |
| Intangible Assets | Rp3.81 Billion | 0.3% |
| Goodwill | Rp53.68 Billion | 3.9% |
Asset Composition Trend (2011–2025)
This chart illustrates how Phapros Tbk PT's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See PEHA stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Phapros Tbk PT's current assets represent 46.3% of total assets in 2025, a decrease from 82.0% in 2011.
- Cash Position: Cash and equivalents constituted 8.7% of total assets in 2025, up from 4.4% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2011.
- Asset Diversification: The largest asset category is property, plant & equipment at 33.7% of total assets.
Phapros Tbk PT Competitors by Total Assets
Key competitors of Phapros Tbk PT based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM
|
India | Rs443.12 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥29.95 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Harbin Pharmaceutical Group Co Ltd
SHG:600664
|
China | CN¥14.08 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
Phapros Tbk PT - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.05 | 1.30 | 0.96 |
| Quick Ratio | 1.55 | 0.99 | 0.62 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rp364.81 Billion | Rp160.14 Billion | Rp-42.65 Billion |
Phapros Tbk PT - Advanced Valuation Insights
This section examines the relationship between Phapros Tbk PT's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.65 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -3.0% |
| Total Assets | Rp1.39 Trillion |
| Market Capitalization | $14.18 Million USD |
Valuation Analysis
Below Book Valuation: The market values Phapros Tbk PT's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Phapros Tbk PT's assets decreased by 3.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Phapros Tbk PT (2011–2025)
The table below shows the annual total assets of Phapros Tbk PT from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Rp1.39 Trillion ≈ $81.28 Million |
-3.00% |
| 2024-12-31 | Rp1.43 Trillion ≈ $83.79 Million |
-19.02% |
| 2023-12-31 | Rp1.77 Trillion ≈ $103.47 Million |
-2.24% |
| 2022-12-31 | Rp1.81 Trillion ≈ $105.84 Million |
-1.75% |
| 2021-12-31 | Rp1.84 Trillion ≈ $107.73 Million |
-4.04% |
| 2020-12-31 | Rp1.92 Trillion ≈ $112.27 Million |
-8.62% |
| 2019-12-31 | Rp2.10 Trillion ≈ $122.86 Million |
+12.20% |
| 2018-12-31 | Rp1.87 Trillion ≈ $109.50 Million |
+58.91% |
| 2017-12-31 | Rp1.18 Trillion ≈ $68.91 Million |
+33.13% |
| 2016-12-31 | Rp883.29 Billion ≈ $51.76 Million |
+29.77% |
| 2015-12-31 | Rp680.65 Billion ≈ $39.88 Million |
+6.67% |
| 2014-12-31 | Rp638.09 Billion ≈ $37.39 Million |
-0.78% |
| 2013-12-31 | Rp643.09 Billion ≈ $37.68 Million |
+15.12% |
| 2012-12-31 | Rp558.64 Billion ≈ $32.73 Million |
+20.76% |
| 2011-12-31 | Rp462.59 Billion ≈ $27.11 Million |
-- |
About Phapros Tbk PT
PT Phapros Tbk, together with its subsidiaries, operates in the pharmaceutical industry in Indonesia. The company operates through Ethical; Over the Counter (OTC) Drugs; Generic Drugs Bearing (OCB); and Toll-in segments. It offers OTC drugs, including Antimo Anak, Antimo tablet, Livron B Plex, Becefort Sirop and tablet, Noza, Febrinex, Betafort suspensi, and Hemorogard. The company also provides … Read more